pharmaceuticals

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent…

19 hours ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and…

3 days ago

Supernus Pharmaceuticals to Participate in March Investor Conferences

February 23, 2026 18:15 ET  | Source: Supernus Pharmaceuticals, Inc. ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,…

1 week ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

February 20, 2026 15:10 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

2 weeks ago

ADARx Pharmaceuticals to Present Onvuzosiran (ADX-324) Phase 1/2 Clinical Data and Phase 3 Design at the 2026 AAAAI Annual Meeting

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA…

2 weeks ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed…

1 month ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

January 26, 2026 17:00 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

1 month ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

January 23, 2026 17:00 ET  | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) --…

1 month ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the…

1 month ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…

2 months ago